Davidtan0629的个人主页 - 老虎社区

Davidtan0629

Davidtan0629

暂无个人介绍

IP属地：未知

71关注

8粉丝

0主题

0勋章

2021-11-12

$Apple(AAPL)$Free

2021-11-12

$Amkor Technology(AMKR)$okay?

2021-11-11

$Apple(AAPL)$free

2021-11-10

$Amkor Technology(AMKR)$okay?

2021-11-09

$Apple(AAPL)$Free

2021-11-09

$Amkor Technology(AMKR)$okay?

2021-11-08

$Amkor Technology(AMKR)$okay?

2021-11-07

$Amkor Technology(AMKR)$okay?

2021-11-06

$Amkor Technology(AMKR)$Okay

2021-11-06

$Apple(AAPL)$Free

2021-11-05

Okay

抱歉，原内容已删除

2021-11-05

$Apple(AAPL)$Free

2021-11-05

Okay?

2021-11-04

$Apple(AAPL)$Free

2021-11-04

$American Vanguard(AVD)$Ok

2021-11-04

Ok

Arhaus Prices IPO At $13/Share, Below Expected Range<blockquote>Arhaus 将 IPO 定价为每股 13 美元，低于预期范围</blockquote>

2021-11-04

Ok

Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4097843570260640","uuid":"4097843570260640","gmtCreate":1634741839658,"gmtModify":1635143360652,"name":"Davidtan0629","pinyin":"davidtan0629","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":71,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":879166305,"gmtCreate":1636691625049,"gmtModify":1636691625263,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/b2ea95fe0dc4d24bdae94bf223165770","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879166305","isVote":1,"tweetType":1,"viewCount":3983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879163128,"gmtCreate":1636691375750,"gmtModify":1636691375845,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/2ce3116aa6b4350089cac219494eb25b","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879163128","isVote":1,"tweetType":1,"viewCount":4205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870549748,"gmtCreate":1636638253209,"gmtModify":1636638253348,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","text":"$Apple(AAPL)$free","images":[{"img":"https://static.tigerbbs.com/0fa87f4736687b257293ed3505545396","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870549748","isVote":1,"tweetType":1,"viewCount":5365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870026378,"gmtCreate":1636559712222,"gmtModify":1636559712222,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/ad973bdec8d500600f36d8180cfc9f25","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870026378","isVote":1,"tweetType":1,"viewCount":4396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794297,"gmtCreate":1636458218209,"gmtModify":1636458314541,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/9fec035c7c2f3a91c0c32ec3290603a0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794297","isVote":1,"tweetType":1,"viewCount":2297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794808,"gmtCreate":1636458194210,"gmtModify":1636458313693,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/802e6ea253bbeee5d32a09f93596940f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794808","isVote":1,"tweetType":1,"viewCount":3472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845563391,"gmtCreate":1636352069137,"gmtModify":1636352272524,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/b296d20f8b90f6acc0fc3135fae30ad6","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845563391","isVote":1,"tweetType":1,"viewCount":4468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845023587,"gmtCreate":1636255086159,"gmtModify":1636255086273,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/af1cdedcb5b54ff460c5934661371810","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845023587","isVote":1,"tweetType":1,"viewCount":3859,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842821933,"gmtCreate":1636163416359,"gmtModify":1636163696964,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>Okay","text":"$Amkor Technology(AMKR)$Okay","images":[{"img":"https://static.tigerbbs.com/033b52d3c21cc3916a69ca9a560f5dba","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842821933","isVote":1,"tweetType":1,"viewCount":4083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842867488,"gmtCreate":1636163241751,"gmtModify":1636163684042,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/d67a60cd910e8ef21b04ae677a44b4ea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842867488","isVote":1,"tweetType":1,"viewCount":5020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846652386,"gmtCreate":1636080271609,"gmtModify":1636080743345,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846652386","repostId":"1128227989","repostType":4,"isVote":1,"tweetType":1,"viewCount":962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846656653,"gmtCreate":1636080241847,"gmtModify":1636080739165,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/4477dd69453f4c2e8bc2616db685ec6f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846656653","isVote":1,"tweetType":1,"viewCount":1251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846658892,"gmtCreate":1636080169281,"gmtModify":1636080380974,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Okay?","listText":"Okay?","text":"Okay?","images":[{"img":"https://static.tigerbbs.com/d3b8a38c328276886fcf41dcc72d5eaa","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846658892","isVote":1,"tweetType":1,"viewCount":918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708774,"gmtCreate":1636025819389,"gmtModify":1636025819525,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/fbc90e86e784bd2218754448be60cb4b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848708774","isVote":1,"tweetType":1,"viewCount":913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708268,"gmtCreate":1636025788188,"gmtModify":1636025788281,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","listText":"<a href=\"https://laohu8.com/S/AVD\">$American Vanguard(AVD)$</a>Ok","text":"$American Vanguard(AVD)$Ok","images":[{"img":"https://static.tigerbbs.com/d409c2b50b3a6a888bc10f403cdc20ed","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848708268","isVote":1,"tweetType":1,"viewCount":1283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848701785,"gmtCreate":1636025698557,"gmtModify":1636025698632,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701785","repostId":"1127498048","repostType":4,"repost":{"id":"1127498048","kind":"news","pubTimestamp":1636021104,"share":"https://www.laohunote.com/m/news/1127498048?lang=zh_CN&edition=full","pubTime":"2021-11-04 18:18","market":"us","language":"en","title":"Arhaus Prices IPO At $13/Share, Below Expected Range<blockquote>Arhaus 将 IPO 定价为每股 13 美元，低于预期范围</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1127498048","media":"Benzinga","summary":"Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 ","content":"<p><div> Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share. The company had expected to price the IPO at $14 -$17 earlier. ...</p><p><blockquote><div>家居零售商 Arhaus Inc NASDAQARHShas 将其 1290 万股首次公开募股 (IPO) 的定价为每股 13.00 美元。该公司早些时候预计IPO的定价为14-17美元。...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arhaus Prices IPO At $13/Share, Below Expected Range<blockquote>Arhaus 将 IPO 定价为每股 13 美元，低于预期范围</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArhaus Prices IPO At $13/Share, Below Expected Range<blockquote>Arhaus 将 IPO 定价为每股 13 美元，低于预期范围</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-11-04 18:18</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share. The company had expected to price the IPO at $14 -$17 earlier. ...</p><p><blockquote><div>家居零售商 Arhaus Inc NASDAQARHShas 将其 1290 万股首次公开募股 (IPO) 的定价为每股 13.00 美元。该公司早些时候预计IPO的定价为14-17美元。...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARHS":"Arhaus, Inc."},"source_url":"https://www.benzinga.com/news/21/11/23882212/arhaus-prices-ipo-at-13share-below-expected-range","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127498048","content_text":"Home furnishings retailer Arhaus Inc NASDAQARHShas priced its initial public offering (IPO) of 12.9 million shares at $13.00 per share.\nThe company had expected to price the IPO at $14 -$17 earlier.\nThe underwriters will have a 30-day option to purchase up to an additional 1.9 million shares from the company.\nThe shares are expected to begin trading on the Nasdaq Global Select Market on Thursday, November 4, 2021, under the ticker symbol \"ARHS.\"\nThe offering is expected to close on November 8, 2021, subject to customary closing conditions.\nBofA Securities and Jefferies LLC are acting as joint lead book-running managers and as representatives for the proposed offering.","news_type":1,"symbols_score_info":{"ARHS":0.9}},"isVote":1,"tweetType":1,"viewCount":921,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848701529,"gmtCreate":1636025670496,"gmtModify":1636025670585,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097843570260640","authorIdStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701529","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohunote.com/m/news/1101079537?lang=zh_CN&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna 下调今年 Covid-19 疫苗销售预测并未达到第三季度盈利和收入预期，股价暴跌 9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna 第三季度收入为 49.69 亿美元，而去年同期为 1.57 亿美元；FactSet 共识 62 亿美元；</li></ul><ul><li>Moderna 第三季度每股收益 7.70 美元，而一年前每股亏损 59 美分；FactSet 共识 9.09 美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天公布了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入 50 亿美元，净利润 33 亿美元，摊薄每股收益 7.70 美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国食品药品监督管理局批准优先审查 Moderna 的 COVID-19 疫苗生物制剂许可申请</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中的2/3期KidCOVE研究的中期数据显示，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺治疗模式：Vertex 和 Moderna 囊性纤维化 mRNA 治疗 (VXc-522) IND 支持的首个人体研究正在进行中</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有 37 个项目正在开发中，其中 21 个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最新进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗开发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>Moderna新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）。美国食品药品监督管理局 (U.S.FDA)、欧盟委员会和瑞士医疗公司批准 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>在6至12岁以下儿童中进行的mRNA-1273的2/3期KidCOVE研究的新数据显示，使用COVID-19的3期COVE研究主要病例定义，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</li><li>针对新冠肺炎（mRNA-1283）的下一代候选疫苗1期研究已全部入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感疫苗候选疫苗（mRNA-1010）的1/2期研究的1期部分已全部入组，研究的2期部分准备工作正在进行中</li><li>呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）在老年人中的关键2/3期研究预计将于2021年开始；研究预计将招募约 34,000 名参与者，但须与监管机构达成协议</li><li>新型呼吸道联合疫苗：Moderna COVID-19疫苗+流感疫苗候选物（mRNA-1073）和儿科RSV+hMPV疫苗候选物（mRNA-1365）</li></ul><i>潜伏疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</li><li>EBV候选疫苗（mRNA-1189）1期研究有望很快启动</li><li>新型EBV治疗性候选疫苗（mRNA-1195）</li></ul><i>治疗</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默沙东帕博利珠单抗（KEYTRUDA）的2期随机、安慰剂对照研究®)，与单用派姆单抗相比，用于辅助治疗高危切除黑色素瘤完全入组；预计2022年第四季度数据读数</li><li>丙酸血症候选药物（mRNA-3927）1/2期Paramount研究完成首个队列入组</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）的1期研究中首例患者给药</li><li>GSD1a 计划 (mRNA-3745) 获得 byU.S.FDA 开放和孤儿药资格的研究性新药申请 (IND)</li><li>向改变生活药物研究所(ILCM)免费提供研究性mRNA Crigler-Najjar综合征1型(CN-1)疗法(mRNA-3351)；CN-1是一种极其罕见的疾病</li><li>引入吸入肺治疗模式；Vertex 和 ModernaMRNA 囊性纤维化 (CF) 治疗剂 (VXc-522) 的 IND 首例人体研究正在新的肺部模式中进行</li></ul>Moderna 继续扩大规模，目前有 37 个项目正在开发中，涉及 34 个开发候选项目1，其中 21 个项目正在进行临床研究。该公司更新后的管道可在 www.modernatx.com/pipeline.moderna 上找到，合作者已经发表了近 100 篇同行评审稿件。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新的财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年（FY）的预期交付：</b>预计 2021 财年产品销售额将在 150 亿至 180 亿美元之间。</li><li></li><li><b>2021财年的疫苗剂量交付：</b>该公司预计 2021 财年 100 µg 剂量水平的 COVID-19 疫苗交付量将在 7 亿至 8 亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期延长，这可能会将交付时间推迟到 2022 年初，灌装/精加工能力扩张的暂时影响以及产品投放市场的增加。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售的百分比预计在16-17%之间。</li><li><b>2021 年研发 (R&amp;D) 和销售、一般和行政 (SG&amp;A) 费用：</b>随着商业和研发活动及费用的增加，预计 2021 年研发和 SG&amp;A 费用将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合和累计净运营亏损结转 23 亿美元，该公司目前预计 2021 年的有效税率将在高个位数范围内。</li><li><b>资本开支：</b>预计 2021 年资本投资约为 4 亿美元。</li><li><b>股份购回计划：</b>董事会已授权在两年内实施高达 10 亿美元的股票回购计划，以将多余资本返还给股东。截至第三季度末，没有股票被回购。</li></ul><b>2022 年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计几个动态将推动 2022 年收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署：</b>该公司已签署约 170 亿美元的预购协议 (APA)，将于 2022 年交付。</li><li><b>具有选项的APA：</b>该公司预计 2022 年 APA 下的期权行使量高达 30 亿美元。</li><li><b>美国2022 年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的 BLA 或 sBLA，该公司预计商业助推器市场销售额可能高达 20 亿美元。</li></ul>根据这三个收入驱动因素，该公司认为 2022 年销售额可能在 170 亿至 220 亿美元之间。该公司继续与各国政府和国际组织讨论 2022 年 APA，包括 COVAX、泛美卫生组织 (PAHO) 和非洲联盟。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna 下调今年 Covid-19 疫苗销售预测并未达到第三季度盈利和收入预期，股价暴跌 9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna 第三季度收入为 49.69 亿美元，而去年同期为 1.57 亿美元；FactSet 共识 62 亿美元；</li></ul><ul><li>Moderna 第三季度每股收益 7.70 美元，而一年前每股亏损 59 美分；FactSet 共识 9.09 美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天公布了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入 50 亿美元，净利润 33 亿美元，摊薄每股收益 7.70 美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国食品药品监督管理局批准优先审查 Moderna 的 COVID-19 疫苗生物制剂许可申请</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中的2/3期KidCOVE研究的中期数据显示，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺治疗模式：Vertex 和 Moderna 囊性纤维化 mRNA 治疗 (VXc-522) IND 支持的首个人体研究正在进行中</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有 37 个项目正在开发中，其中 21 个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最新进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗开发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>Moderna新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）。美国食品药品监督管理局 (U.S.FDA)、欧盟委员会和瑞士医疗公司批准 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>在6至12岁以下儿童中进行的mRNA-1273的2/3期KidCOVE研究的新数据显示，使用COVID-19的3期COVE研究主要病例定义，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</li><li>针对新冠肺炎（mRNA-1283）的下一代候选疫苗1期研究已全部入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感疫苗候选疫苗（mRNA-1010）的1/2期研究的1期部分已全部入组，研究的2期部分准备工作正在进行中</li><li>呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）在老年人中的关键2/3期研究预计将于2021年开始；研究预计将招募约 34,000 名参与者，但须与监管机构达成协议</li><li>新型呼吸道联合疫苗：Moderna COVID-19疫苗+流感疫苗候选物（mRNA-1073）和儿科RSV+hMPV疫苗候选物（mRNA-1365）</li></ul><i>潜伏疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</li><li>EBV候选疫苗（mRNA-1189）1期研究有望很快启动</li><li>新型EBV治疗性候选疫苗（mRNA-1195）</li></ul><i>治疗</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默沙东帕博利珠单抗（KEYTRUDA）的2期随机、安慰剂对照研究®)，与单用派姆单抗相比，用于辅助治疗高危切除黑色素瘤完全入组；预计2022年第四季度数据读数</li><li>丙酸血症候选药物（mRNA-3927）1/2期Paramount研究完成首个队列入组</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）的1期研究中首例患者给药</li><li>GSD1a 计划 (mRNA-3745) 获得 byU.S.FDA 开放和孤儿药资格的研究性新药申请 (IND)</li><li>向改变生活药物研究所(ILCM)免费提供研究性mRNA Crigler-Najjar综合征1型(CN-1)疗法(mRNA-3351)；CN-1是一种极其罕见的疾病</li><li>引入吸入肺治疗模式；Vertex 和 ModernaMRNA 囊性纤维化 (CF) 治疗剂 (VXc-522) 的 IND 首例人体研究正在新的肺部模式中进行</li></ul>Moderna 继续扩大规模，目前有 37 个项目正在开发中，涉及 34 个开发候选项目1，其中 21 个项目正在进行临床研究。该公司更新后的管道可在 www.modernatx.com/pipeline.moderna 上找到，合作者已经发表了近 100 篇同行评审稿件。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新的财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年（FY）的预期交付：</b>预计 2021 财年产品销售额将在 150 亿至 180 亿美元之间。</li><li></li><li><b>2021财年的疫苗剂量交付：</b>该公司预计 2021 财年 100 µg 剂量水平的 COVID-19 疫苗交付量将在 7 亿至 8 亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期延长，这可能会将交付时间推迟到 2022 年初，灌装/精加工能力扩张的暂时影响以及产品投放市场的增加。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售的百分比预计在16-17%之间。</li><li><b>2021 年研发 (R&amp;D) 和销售、一般和行政 (SG&amp;A) 费用：</b>随着商业和研发活动及费用的增加，预计 2021 年研发和 SG&amp;A 费用将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合和累计净运营亏损结转 23 亿美元，该公司目前预计 2021 年的有效税率将在高个位数范围内。</li><li><b>资本开支：</b>预计 2021 年资本投资约为 4 亿美元。</li><li><b>股份购回计划：</b>董事会已授权在两年内实施高达 10 亿美元的股票回购计划，以将多余资本返还给股东。截至第三季度末，没有股票被回购。</li></ul><b>2022 年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计几个动态将推动 2022 年收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署：</b>该公司已签署约 170 亿美元的预购协议 (APA)，将于 2022 年交付。</li><li><b>具有选项的APA：</b>该公司预计 2022 年 APA 下的期权行使量高达 30 亿美元。</li><li><b>美国2022 年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的 BLA 或 sBLA，该公司预计商业助推器市场销售额可能高达 20 亿美元。</li></ul>根据这三个收入驱动因素，该公司认为 2022 年销售额可能在 170 亿至 220 亿美元之间。该公司继续与各国政府和国际组织讨论 2022 年 APA，包括 COVAX、泛美卫生组织 (PAHO) 和非洲联盟。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":846652386,"gmtCreate":1636080271609,"gmtModify":1636080743345,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846652386","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","kind":"news","pubTimestamp":1636067303,"share":"https://www.laohunote.com/m/news/1128227989?lang=zh_CN&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>(路透社）--标普500和纳斯达克周四上涨，将连续六个交易日的历史新高收盘纪录延长，原因是高通（Qualcomm）强劲的财务预测以及投资者消化了美联储开始减少每月债券购买量的决定后，芯片制造商股价大涨。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了连续四点收盘的纪录。摩根大通和高盛集团银行股的下跌给蓝筹股指数带来压力。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>由于美国国债收益率下降，金融股下跌 1.3%，其中大部分是标普500板块，在美联储表示不急于加息的第二天，市场放松了对美联储加快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>“约翰-汉考克投资管理公司（John Hancock Investment Management）联席首席投资策略师马修-米斯金（Matthew Miskin）说：”今天，市场的增长端看到了更多积极的结果，因为它们受益于收益率的下降。</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减收益率，市场总体上一直在为更高的收益率做好准备。当我们今天走进去时，这种情况发生了逆转”。</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌 33.35 点，或 0.09%，至 36,124.23 点；标普500指数上涨 19.49 点，或 0.42%，至 4,680.06 点；纳斯达克综合指数上涨 128.72 点，或 0.81%，至 15,940.31 点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>在标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨 12.7%，该公司预测本季度利润和收入将好于预期，原因是手机、汽车和其他互联网连接设备中使用的芯片需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城东南半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度盈利有助于提振股市情绪。据 Refinitiv IBES 称，由于约有 420 家公司提交了报告，标普500第三季度盈利预计将比去年同期增长 41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>“爱德华-琼斯（Edward Jones）投资策略师克雷格-费尔（Craig Fehr）说：”企业盈利情况仍然相当光明。</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些未能达到本季度预期的公司，更重要的是，也许是预示着前景更加黯淡的公司。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna 股价暴跌约 18%，该公司将 2021 年 COVID-19 疫苗的销售预测削减了多达 50 亿美元，努力填充小瓶并进行分销，以满足前所未有的全球需求。Moderna 股价拖累标普500医疗保健板块，该板块下跌 0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在重获动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌发行量与上涨发行量的比例为 1.12 比 1；在纳斯达克，1.24 比 1 的比率有利于下跌者。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下 75 个 52 周新高和 5 个新低；纳斯达克综合指数创下224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有 113 亿股股票易手，高于过去 20 个交易日的日均 104 亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-05 07:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>(路透社）--标普500和纳斯达克周四上涨，将连续六个交易日的历史新高收盘纪录延长，原因是高通（Qualcomm）强劲的财务预测以及投资者消化了美联储开始减少每月债券购买量的决定后，芯片制造商股价大涨。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了连续四点收盘的纪录。摩根大通和高盛集团银行股的下跌给蓝筹股指数带来压力。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>由于美国国债收益率下降，金融股下跌 1.3%，其中大部分是标普500板块，在美联储表示不急于加息的第二天，市场放松了对美联储加快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>“约翰-汉考克投资管理公司（John Hancock Investment Management）联席首席投资策略师马修-米斯金（Matthew Miskin）说：”今天，市场的增长端看到了更多积极的结果，因为它们受益于收益率的下降。</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减收益率，市场总体上一直在为更高的收益率做好准备。当我们今天走进去时，这种情况发生了逆转”。</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌 33.35 点，或 0.09%，至 36,124.23 点；标普500指数上涨 19.49 点，或 0.42%，至 4,680.06 点；纳斯达克综合指数上涨 128.72 点，或 0.81%，至 15,940.31 点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>在标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨 12.7%，该公司预测本季度利润和收入将好于预期，原因是手机、汽车和其他互联网连接设备中使用的芯片需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城东南半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度盈利有助于提振股市情绪。据 Refinitiv IBES 称，由于约有 420 家公司提交了报告，标普500第三季度盈利预计将比去年同期增长 41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>“爱德华-琼斯（Edward Jones）投资策略师克雷格-费尔（Craig Fehr）说：”企业盈利情况仍然相当光明。</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些未能达到本季度预期的公司，更重要的是，也许是预示着前景更加黯淡的公司。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna 股价暴跌约 18%，该公司将 2021 年 COVID-19 疫苗的销售预测削减了多达 50 亿美元，努力填充小瓶并进行分销，以满足前所未有的全球需求。Moderna 股价拖累标普500医疗保健板块，该板块下跌 0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在重获动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌发行量与上涨发行量的比例为 1.12 比 1；在纳斯达克，1.24 比 1 的比率有利于下跌者。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下 75 个 52 周新高和 5 个新低；纳斯达克综合指数创下224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有 113 亿股股票易手，高于过去 20 个交易日的日均 104 亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","OEX":"标普100",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF-ProShares","SSO":"2倍做多标普500ETF-ProShares",".DJI":"道琼斯","IVV":"标普500ETF-iShares","OEF":"标普100指数ETF-iShares",".IXIC":"NASDAQ Composite","SDS":"两倍做空标普500 ETF-ProShares","SH":"做空标普500-Proshares","UPRO":"三倍做多标普500ETF-ProShares"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".IXIC":0.9,"IVV":0.9,"OEF":0.9,"SDS":0.9,"SH":0.9,".DJI":0.9,"UPRO":0.9,"ESmain":0.9,"OEX":0.9,".SPX":0.9,"SSO":0.9,"SPXU":0.9}},"isVote":1,"tweetType":1,"viewCount":962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848701529,"gmtCreate":1636025670496,"gmtModify":1636025670585,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848701529","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohunote.com/m/news/1101079537?lang=zh_CN&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna 下调今年 Covid-19 疫苗销售预测并未达到第三季度盈利和收入预期，股价暴跌 9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna 第三季度收入为 49.69 亿美元，而去年同期为 1.57 亿美元；FactSet 共识 62 亿美元；</li></ul><ul><li>Moderna 第三季度每股收益 7.70 美元，而一年前每股亏损 59 美分；FactSet 共识 9.09 美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天公布了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入 50 亿美元，净利润 33 亿美元，摊薄每股收益 7.70 美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国食品药品监督管理局批准优先审查 Moderna 的 COVID-19 疫苗生物制剂许可申请</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中的2/3期KidCOVE研究的中期数据显示，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺治疗模式：Vertex 和 Moderna 囊性纤维化 mRNA 治疗 (VXc-522) IND 支持的首个人体研究正在进行中</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有 37 个项目正在开发中，其中 21 个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最新进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗开发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>Moderna新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）。美国食品药品监督管理局 (U.S.FDA)、欧盟委员会和瑞士医疗公司批准 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>在6至12岁以下儿童中进行的mRNA-1273的2/3期KidCOVE研究的新数据显示，使用COVID-19的3期COVE研究主要病例定义，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</li><li>针对新冠肺炎（mRNA-1283）的下一代候选疫苗1期研究已全部入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感疫苗候选疫苗（mRNA-1010）的1/2期研究的1期部分已全部入组，研究的2期部分准备工作正在进行中</li><li>呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）在老年人中的关键2/3期研究预计将于2021年开始；研究预计将招募约 34,000 名参与者，但须与监管机构达成协议</li><li>新型呼吸道联合疫苗：Moderna COVID-19疫苗+流感疫苗候选物（mRNA-1073）和儿科RSV+hMPV疫苗候选物（mRNA-1365）</li></ul><i>潜伏疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</li><li>EBV候选疫苗（mRNA-1189）1期研究有望很快启动</li><li>新型EBV治疗性候选疫苗（mRNA-1195）</li></ul><i>治疗</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默沙东帕博利珠单抗（KEYTRUDA）的2期随机、安慰剂对照研究®)，与单用派姆单抗相比，用于辅助治疗高危切除黑色素瘤完全入组；预计2022年第四季度数据读数</li><li>丙酸血症候选药物（mRNA-3927）1/2期Paramount研究完成首个队列入组</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）的1期研究中首例患者给药</li><li>GSD1a 计划 (mRNA-3745) 获得 byU.S.FDA 开放和孤儿药资格的研究性新药申请 (IND)</li><li>向改变生活药物研究所(ILCM)免费提供研究性mRNA Crigler-Najjar综合征1型(CN-1)疗法(mRNA-3351)；CN-1是一种极其罕见的疾病</li><li>引入吸入肺治疗模式；Vertex 和 ModernaMRNA 囊性纤维化 (CF) 治疗剂 (VXc-522) 的 IND 首例人体研究正在新的肺部模式中进行</li></ul>Moderna 继续扩大规模，目前有 37 个项目正在开发中，涉及 34 个开发候选项目1，其中 21 个项目正在进行临床研究。该公司更新后的管道可在 www.modernatx.com/pipeline.moderna 上找到，合作者已经发表了近 100 篇同行评审稿件。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新的财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年（FY）的预期交付：</b>预计 2021 财年产品销售额将在 150 亿至 180 亿美元之间。</li><li></li><li><b>2021财年的疫苗剂量交付：</b>该公司预计 2021 财年 100 µg 剂量水平的 COVID-19 疫苗交付量将在 7 亿至 8 亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期延长，这可能会将交付时间推迟到 2022 年初，灌装/精加工能力扩张的暂时影响以及产品投放市场的增加。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售的百分比预计在16-17%之间。</li><li><b>2021 年研发 (R&amp;D) 和销售、一般和行政 (SG&amp;A) 费用：</b>随着商业和研发活动及费用的增加，预计 2021 年研发和 SG&amp;A 费用将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合和累计净运营亏损结转 23 亿美元，该公司目前预计 2021 年的有效税率将在高个位数范围内。</li><li><b>资本开支：</b>预计 2021 年资本投资约为 4 亿美元。</li><li><b>股份购回计划：</b>董事会已授权在两年内实施高达 10 亿美元的股票回购计划，以将多余资本返还给股东。截至第三季度末，没有股票被回购。</li></ul><b>2022 年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计几个动态将推动 2022 年收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署：</b>该公司已签署约 170 亿美元的预购协议 (APA)，将于 2022 年交付。</li><li><b>具有选项的APA：</b>该公司预计 2022 年 APA 下的期权行使量高达 30 亿美元。</li><li><b>美国2022 年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的 BLA 或 sBLA，该公司预计商业助推器市场销售额可能高达 20 亿美元。</li></ul>根据这三个收入驱动因素，该公司认为 2022 年销售额可能在 170 亿至 220 亿美元之间。该公司继续与各国政府和国际组织讨论 2022 年 APA，包括 COVAX、泛美卫生组织 (PAHO) 和非洲联盟。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results<blockquote>Moderna 公布季度业绩后股价暴跌 9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna 下调今年 Covid-19 疫苗销售预测并未达到第三季度盈利和收入预期，股价暴跌 9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna 第三季度收入为 49.69 亿美元，而去年同期为 1.57 亿美元；FactSet 共识 62 亿美元；</li></ul><ul><li>Moderna 第三季度每股收益 7.70 美元，而一年前每股亏损 59 美分；FactSet 共识 9.09 美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天公布了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入 50 亿美元，净利润 33 亿美元，摊薄每股收益 7.70 美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国食品药品监督管理局批准优先审查 Moderna 的 COVID-19 疫苗生物制剂许可申请</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中的2/3期KidCOVE研究的中期数据显示，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺治疗模式：Vertex 和 Moderna 囊性纤维化 mRNA 治疗 (VXc-522) IND 支持的首个人体研究正在进行中</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有 37 个项目正在开发中，其中 21 个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最新进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗开发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>Moderna新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）。美国食品药品监督管理局 (U.S.FDA)、欧盟委员会和瑞士医疗公司批准 50 µg 剂量水平的 Moderna COVID-19 疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>在6至12岁以下儿童中进行的mRNA-1273的2/3期KidCOVE研究的新数据显示，使用COVID-19的3期COVE研究主要病例定义，在50 µg剂量水平下首次接种mRNA-1273两周后，疫苗效力为100%</li><li>针对新冠肺炎（mRNA-1283）的下一代候选疫苗1期研究已全部入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感疫苗候选疫苗（mRNA-1010）的1/2期研究的1期部分已全部入组，研究的2期部分准备工作正在进行中</li><li>呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）在老年人中的关键2/3期研究预计将于2021年开始；研究预计将招募约 34,000 名参与者，但须与监管机构达成协议</li><li>新型呼吸道联合疫苗：Moderna COVID-19疫苗+流感疫苗候选物（mRNA-1073）和儿科RSV+hMPV疫苗候选物（mRNA-1365）</li></ul><i>潜伏疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒 (CMV) 候选疫苗 (mRNA-1647) 3 期研究的首批参与者接种疫苗</li><li>EBV候选疫苗（mRNA-1189）1期研究有望很快启动</li><li>新型EBV治疗性候选疫苗（mRNA-1195）</li></ul><i>治疗</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默沙东帕博利珠单抗（KEYTRUDA）的2期随机、安慰剂对照研究®)，与单用派姆单抗相比，用于辅助治疗高危切除黑色素瘤完全入组；预计2022年第四季度数据读数</li><li>丙酸血症候选药物（mRNA-3927）1/2期Paramount研究完成首个队列入组</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）的1期研究中首例患者给药</li><li>GSD1a 计划 (mRNA-3745) 获得 byU.S.FDA 开放和孤儿药资格的研究性新药申请 (IND)</li><li>向改变生活药物研究所(ILCM)免费提供研究性mRNA Crigler-Najjar综合征1型(CN-1)疗法(mRNA-3351)；CN-1是一种极其罕见的疾病</li><li>引入吸入肺治疗模式；Vertex 和 ModernaMRNA 囊性纤维化 (CF) 治疗剂 (VXc-522) 的 IND 首例人体研究正在新的肺部模式中进行</li></ul>Moderna 继续扩大规模，目前有 37 个项目正在开发中，涉及 34 个开发候选项目1，其中 21 个项目正在进行临床研究。该公司更新后的管道可在 www.modernatx.com/pipeline.moderna 上找到，合作者已经发表了近 100 篇同行评审稿件。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新的财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年（FY）的预期交付：</b>预计 2021 财年产品销售额将在 150 亿至 180 亿美元之间。</li><li></li><li><b>2021财年的疫苗剂量交付：</b>该公司预计 2021 财年 100 µg 剂量水平的 COVID-19 疫苗交付量将在 7 亿至 8 亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期延长，这可能会将交付时间推迟到 2022 年初，灌装/精加工能力扩张的暂时影响以及产品投放市场的增加。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售的百分比预计在16-17%之间。</li><li><b>2021 年研发 (R&amp;D) 和销售、一般和行政 (SG&amp;A) 费用：</b>随着商业和研发活动及费用的增加，预计 2021 年研发和 SG&amp;A 费用将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合和累计净运营亏损结转 23 亿美元，该公司目前预计 2021 年的有效税率将在高个位数范围内。</li><li><b>资本开支：</b>预计 2021 年资本投资约为 4 亿美元。</li><li><b>股份购回计划：</b>董事会已授权在两年内实施高达 10 亿美元的股票回购计划，以将多余资本返还给股东。截至第三季度末，没有股票被回购。</li></ul><b>2022 年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计几个动态将推动 2022 年收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署：</b>该公司已签署约 170 亿美元的预购协议 (APA)，将于 2022 年交付。</li><li><b>具有选项的APA：</b>该公司预计 2022 年 APA 下的期权行使量高达 30 亿美元。</li><li><b>美国2022 年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的 BLA 或 sBLA，该公司预计商业助推器市场销售额可能高达 20 亿美元。</li></ul>根据这三个收入驱动因素，该公司认为 2022 年销售额可能在 170 亿至 220 亿美元之间。该公司继续与各国政府和国际组织讨论 2022 年 APA，包括 COVAX、泛美卫生组织 (PAHO) 和非洲联盟。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1083,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870549748,"gmtCreate":1636638253209,"gmtModify":1636638253348,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>free","text":"$Apple(AAPL)$free","images":[{"img":"https://static.tigerbbs.com/0fa87f4736687b257293ed3505545396","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870549748","isVote":1,"tweetType":1,"viewCount":5365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848708774,"gmtCreate":1636025819389,"gmtModify":1636025819525,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/fbc90e86e784bd2218754448be60cb4b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848708774","isVote":1,"tweetType":1,"viewCount":913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879166305,"gmtCreate":1636691625049,"gmtModify":1636691625263,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/b2ea95fe0dc4d24bdae94bf223165770","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879166305","isVote":1,"tweetType":1,"viewCount":3983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879163128,"gmtCreate":1636691375750,"gmtModify":1636691375845,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/2ce3116aa6b4350089cac219494eb25b","width":"1080","height":"3162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879163128","isVote":1,"tweetType":1,"viewCount":4205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870026378,"gmtCreate":1636559712222,"gmtModify":1636559712222,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/ad973bdec8d500600f36d8180cfc9f25","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870026378","isVote":1,"tweetType":1,"viewCount":4396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842867488,"gmtCreate":1636163241751,"gmtModify":1636163684042,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/d67a60cd910e8ef21b04ae677a44b4ea","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842867488","isVote":1,"tweetType":1,"viewCount":5020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794297,"gmtCreate":1636458218209,"gmtModify":1636458314541,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Free","text":"$Apple(AAPL)$Free","images":[{"img":"https://static.tigerbbs.com/9fec035c7c2f3a91c0c32ec3290603a0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794297","isVote":1,"tweetType":1,"viewCount":2297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844794808,"gmtCreate":1636458194210,"gmtModify":1636458313693,"author":{"id":"4097843570260640","authorId":"4097843570260640","name":"Davidtan0629","avatar":"https://static.tigerbbs.com/c9dc7706c115679e015b8d9de633b7eb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097843570260640","idStr":"4097843570260640"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","listText":"<a href=\"https://laohu8.com/S/AMKR\">$Amkor Technology(AMKR)$</a>okay?","text":"$Amkor Technology(AMKR)$okay?","images":[{"img":"https://static.tigerbbs.com/802e6ea253bbeee5d32a09f93596940f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844794808","isVote":1,"tweetType":1,"viewCount":3472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}